JP2011505843A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505843A5
JP2011505843A5 JP2010538269A JP2010538269A JP2011505843A5 JP 2011505843 A5 JP2011505843 A5 JP 2011505843A5 JP 2010538269 A JP2010538269 A JP 2010538269A JP 2010538269 A JP2010538269 A JP 2010538269A JP 2011505843 A5 JP2011505843 A5 JP 2011505843A5
Authority
JP
Japan
Prior art keywords
fibrosis
use according
inflammation
ace2
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538269A
Other languages
English (en)
Japanese (ja)
Other versions
JP5706163B2 (ja
JP2011505843A (ja
Filing date
Publication date
Priority claimed from EP07450239A external-priority patent/EP2077119A1/de
Application filed filed Critical
Publication of JP2011505843A publication Critical patent/JP2011505843A/ja
Publication of JP2011505843A5 publication Critical patent/JP2011505843A5/ja
Application granted granted Critical
Publication of JP5706163B2 publication Critical patent/JP5706163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538269A 2007-12-21 2008-12-22 線維症および肝疾患の治療 Active JP5706163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07450239A EP2077119A1 (de) 2007-12-21 2007-12-21 Behandlung von Fibrosen und Lebererkrankungen
EP07450239.4 2007-12-21
PCT/AT2008/000472 WO2009086572A1 (de) 2007-12-21 2008-12-22 Behandlung von fibrosen und lebererkrankungen

Publications (3)

Publication Number Publication Date
JP2011505843A JP2011505843A (ja) 2011-03-03
JP2011505843A5 true JP2011505843A5 (OSRAM) 2012-02-02
JP5706163B2 JP5706163B2 (ja) 2015-04-22

Family

ID=39529812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538269A Active JP5706163B2 (ja) 2007-12-21 2008-12-22 線維症および肝疾患の治療

Country Status (13)

Country Link
US (1) US20100316624A1 (OSRAM)
EP (3) EP2077119A1 (OSRAM)
JP (1) JP5706163B2 (OSRAM)
AU (1) AU2008347208B9 (OSRAM)
CA (1) CA2709895C (OSRAM)
DK (2) DK2572724T3 (OSRAM)
ES (2) ES2671556T3 (OSRAM)
NO (1) NO2572724T3 (OSRAM)
NZ (1) NZ586265A (OSRAM)
PL (2) PL2227246T3 (OSRAM)
PT (2) PT2227246E (OSRAM)
TR (1) TR201807891T4 (OSRAM)
WO (1) WO2009086572A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
EP3893890B1 (en) * 2020-02-20 2025-12-10 Sheau-Long Lee Ginsenoside m1 for use in the treatment of damages in organs or tissues in a subject caused by infection with coronavirus
US20250009853A1 (en) 2021-12-03 2025-01-09 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5582995A (en) * 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5591591A (en) * 1995-02-09 1997-01-07 Tropix, Inc. Dioxetane compounds for the chemiluminescent detection of proteases, methods of use and kits therefore
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6306830B1 (en) * 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
US6224584B1 (en) * 1997-01-14 2001-05-01 Eclipse Surgical Technologies, Inc. Therapeutic and diagnostic agent delivery
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
US5851788A (en) * 1997-01-31 1998-12-22 The Burnham Institute Nucleic acid encoding a family of acetyl-coenzyme-A transporter proteins, and products related thereto
US6037137A (en) * 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US5997509A (en) * 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
WO2000066104A2 (en) * 1999-04-30 2000-11-09 Millennium Pharmaceuticals, Inc. Ace-2 inhibiting compounds and methods of use thereof
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
SI2332582T1 (sl) * 2002-06-19 2014-03-31 Apeiron Biologics Ag Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
US20050287066A1 (en) * 2004-06-28 2005-12-29 Monoace, Inc. Anti-rat angiotensin I-converting enzyme (ACE, CD143) monoclonal antibodies and uses thereof
CA2520514A1 (en) * 2005-04-04 2006-10-04 Monash University Detection of plasma ace2
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
US7842709B2 (en) * 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten

Similar Documents

Publication Publication Date Title
NO20161808A1 (no) Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati
JP2009256391A5 (OSRAM)
UY31765A (es) Dihidropirazolonas sustituidas y su uso
EP2220095A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2019825A4 (en) HEMMER OF THE REPRODUCTION OF HUMAN IMMUNE DEFICIENCY VIRUSES
BRPI0816128A2 (pt) Uso de uma composição de estabilização, composição de estabilização, produto de cuidado corporal, e, produto doméstico.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
JP2010525073A5 (OSRAM)
EP2367808A4 (en) PROGESTATIVE 3- (6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-EN-17a-YL) PROPIONIC ACID g-LACTONE
EP2252671A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND DIMETHOXYMETHANE
NI201000211A (es) Dronedarona para la prevención de la fibrilación auricular permanente.
CY1116931T1 (el) Στοματικο σκευασμα μεταδοξινης
CL2012003168A1 (es) Composicion farmaceutica que comprende una solucion acuosa de minociclina y un cation divalente o trivalente en una proporcion mayor de 2:1 con respecto a la minociclina; metodo de preparacion; kit y uso en el tratamiento de infecciones bacterianas.
JP2009536926A5 (OSRAM)
JP2011510778A5 (OSRAM)
WO2013020094A3 (en) Novel hemostatic patch and uses thereof
ITRM20090489A1 (it) Sequenze oligonucleotidiche inibitrici dellâ¬"espressione della chimera ciclina d1/trop2 e loro uso in campo medico.
JP2009001575A5 (OSRAM)
UY30198A1 (es) Dominios kunitz quiméricos y su uso
JP2009242695A5 (OSRAM)
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
JP2009507965A5 (OSRAM)
JP2011008097A5 (OSRAM)
JP2008514670A5 (OSRAM)
DK1906994T3 (da) Luftvejsadministration af aktiveret protein C ved inflammatoriske tilstande, som angriber åndedrætsorganerne